
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is attractive because it is concentrating its limited clinical and financial resources on late-stage pancreatic cancer, a disease with more than 450,000 deaths worldwide as recently as 2022 and substantial unmet need. The company’s DURIPANC Phase 2 study, run with AstraZeneca and Erasmus MC, has enrolled 18 subjects, with key clinical benefit data expected in Q1 2027 and overall survival data in Q3 2027, giving investors multiple near-term catalysts. Although AIM remains early stage with a Q1 2026 net loss of $3.0 million, $6 million in cash, and $4 million in debt, positive safety and efficacy signals, plus other ongoing trials, support a high-risk, high-reward outlook.
Bears say
AIM ImmunoTech is pressured by its clinical-stage profile, which keeps revenue minimal while exposing the company to heavy reliance on successful trial outcomes, regulatory approvals, and eventual commercialization of Ampligen and Alferon N. Its Q2 2026 results, reported on August 10, showed a $7 million net loss, or $(0.43) per share, materially worse than the $(0.12) to $(0.17) estimates, underscoring weak operating leverage and continued earnings shortfall. The outlook is further weakened by balance sheet and liquidity risk, reimbursement uncertainty, competitive pressures, and the possibility that changing macroeconomic conditions and biotech investor sentiment could keep funding and valuation under pressure.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AIM ImmunoTech Inc (AIM) Forecast
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares